Background {#Sec1}
==========

Prostate cancer is the most frequently diagnosed cancer among Spanish men. With an incidence of 65.2 per 100 000 persons per year (27 853 new cases yearly 21.7 % of the total cancer in men), it is overall the second most frequent cancer in Spain \[[@CR1]\]. Worldwide, it is the second most frequently diagnosed cancer among men (1 111 689 new cases, 15.0 % of all cancers in men) and overall the fourth most common cancer \[[@CR1]\]. The incidence of prostate cancer has increased over the last decades, partly due to the more frequent use of diagnostic tools such as prostate-specific antigen (PSA) testing and needle biopsies in asymptomatic men \[[@CR2]--[@CR4]\]. The impact on mortality is high. Mortality rates in Spain showed a slight increase between 1980 and 1998 but have since decreased \[[@CR5], [@CR6]\]. In 2012, the estimated mortality associated with prostate cancer was 5481 in Spain and 307 471 worldwide, making it the third leading cause of death due to cancer for men in Spain (8.6 % of the total) and the sixth leading cause worldwide (6.6 % of the total) \[[@CR1]\]. Furthermore, prostate cancer reduces the quality of life of patients \[[@CR7], [@CR8]\].

The economic burden of prostate cancer is one of the largest among malignant tumours due to the high incidence of the disease and increasing survival rates \[[@CR9]\]. It is estimated to cost 11.85 billion USD annually in the USA \[[@CR9]\]. Total costs for diagnosing, treating, and monitoring patients with prostate cancer for five years have been estimated to be approximately £7294.2 per patient and £92.74 million overall in the United Kingdom \[[@CR10]\].

The Spanish Health System is funded by taxes. It offers universal coverage and is managed regionally within each of the 17 autonomous communities. Healthcare is divided into two broad areas, primary care and hospital care. Prostate cancer is generally detected in primary care centres, where patients might undergo some diagnostic tests. For confirmatory tests, however, such as a prostate biopsy, the patient is referred to a hospital for specialised healthcare. Direct access to specialised healthcare may also occur through the hospital emergency services, but this is less frequent.

Several international initiatives have been launched to obtain detailed and reliable information regarding the healthcare process for prostate cancer patients. This information includes the time intervals between first consultation to diagnosis, and first treatment. Such projects include The European Cancer Registry-based Study of Survival and Care of Cancer Patients (EUROCARE) \[[@CR11]\], the Patient Outcome Research Teams (PORTS) \[[@CR12]\], and the Cancer of the Prostate Strategic Urologic Research Endeavour (CAPSURE) \[[@CR13]\]. Information can also be obtained from databases containing regional and national incidence and mortality statistics, from hospital minimum data sets, and from hospital-based cancer registries that allow a description and generic comparison of hospital healthcare \[[@CR14], [@CR15]\]. These sources of information, however, do not include the type of data needed to identify the diagnostic processes, therapeutic approaches, and prognostic factors in prostate cancer. Recently, one study regarding prostate cancer has been conducted in Spain, with the objective to estimate prostate cancer incidence and profile the newly-diagnosed cases using a nationwide hospital-based registry \[[@CR16], [@CR17]\]. However, this study fails to examine the diagnosis and therapeutic processes and possible factors influencing these time intervals. The objective of the EMPARO-CU study is to examine the clinical care process and health outcomes of patients with urologic tumours during the first year from the histopathological prostate cancer confirmation. In this paper we describe the patients' baseline characteristics at hospital entry and the time intervals between the first consultation and diagnosis, and between diagnosis and start of treatment and possible factors influencing these intervals.

Methods {#Sec2}
=======

The EMPARO-CU study is a multicentre, cohort study of bladder and prostate cancer, conducted in seven tertiary hospitals in Spain: *Fundació Puigvert-Hospital de la Santa Creu i Sant Pau* (coordinating centre) and *Hospital del Mar* in Barcelona*, Hospital Universitario 12 de Octubre* and *Hospital Universitario Ramón y Cajal* in Madrid, *Hospital Universitario Donostia* in Donostia-San Sebastián, *Hospital General Universitario de Valencia* in Valencia, and *Hospital Universitario Virgen de las Nieves* in Granada (list of participants in [Appendix](#Sec6){ref-type="sec"}). The protocol was approved by the research ethics committees at each participating centre (Table [1](#Tab1){ref-type="table"}). Patients were enrolled from October 2010 to September 2011. Consecutive patients were selected from the urologic and oncology departments at each centre. Inclusion criteria were: 1) diagnosis of prostate cancer during the study period, independently of the tumour stage; 2) diagnosis and treatment at one of the participating hospitals; and 3) agreement to participate and signed informed consent.Table 1List of ethic committees that approval the studyHospital de la Santa Creu i Sant Pau (Barcelona)Fundación Puigvert (Barcelona)Hospital 12 de Octubre (Madrid)Hospital Ramón y Cajal (Madrid)Autonómico del País VascoHospital Donosti (San Sebastián)Hospital General Universitario de ValenciaHospital Nuestra Señora del Mar (Barcelona)Hospital Virgen de las Nieves (Granada)

The EMPARO-CU study focuses on the clinical care process and health outcomes of patients with urologic tumours. In this paper we describe the patients' baseline characteristics at hospital entry and the intervals between the first consultation and diagnosis, and between diagnosis and start of treatment. Information regarding patient status before the diagnosis (such as symptoms at first visit) was collected retrospectively. Study data were collected from the medical records and from structured interviews with individual patients. Variables of interest were: socio-demographic data, body mass index (BMI), Charlson index, ECOG WHO score, first specialist consulted, diagnostic tests performed to establish a diagnosis of prostate cancer, pathological results of prostate biopsy \[[@CR18]\], PSA values, total Gleason scores, clinical stages, time from first symptom to first consultation, and time from first consultation to primary diagnosis and first treatment (Fig. [1](#Fig1){ref-type="fig"}). Time from first symptom to first consultation was defined as the date on which the patients experienced the first symptoms related to prostate cancer. The date of first consultation was considered the date on which the patient first consulted a healthcare professional for the symptoms that led to prostate cancer screening. For asymptomatic patients, the first consultation was considered the date on which the physician performed prostate screening. We considered the first histological confirmation as the confirmatory diagnosis of the disease. The reference date to calculate intervals was the date of biopsy that confirmed the histological diagnosis of prostate cancer. The time interval between the first consultation and biopsy was considered the diagnostic interval. The time between the biopsy and first treatment was considered the therapeutic interval.Fig. 1Time intervals considered in our study

Categorical variables are described using relative frequency, and continuous variables are described using mean and standard deviation (SD) or median and interquartile range (IQR) for skewed distribution variables. The frequency of missing values is reported for each variable.

The association between time variables and potential predictors was assessed using multilevel (patients at first level and hospitals at second level) logistic regression models. The variables included as potential predictors in both models were age, BMI, education level, ECOG WHO score, specialist at first consultation, primary tumour clinical stage, PSA value, Gleason score, and presence of prostate cancer symptoms. Continuous time variables were transformed into dichotomous variables. In agreement with previous studies, cut-offs chosen were an interval of 100 days between first consultation and diagnosis and 30 days between diagnosis and treatment \[[@CR19], [@CR20]\]. These intervals were based on recommendations about optimal diagnostic and therapeutic intervals \[[@CR21], [@CR22]\]. We first fitted an empty model that considered only the random effect of the hospital on the variability of the two outcomes investigated. We then fitted univariate models with each potential predictor. The final model was fitted through a backward selection procedure based on Wald tests results. Both the empty model and the final multilevel models were estimated by maximum likelihood based on Gaussian quadrature points \[[@CR23]\].

To estimate the random inter-hospital variability, we used the intra-cluster correlation coefficient (ICC) and the median odds ratio (MOR). The ICC indicates the fraction of the total outcome variability that is attributable to the area level (in our case, hospital level) and provides a measure of the within-hospital homogeneity. A lower ICC indicates a lower likelihood of patients' sharing hospital experiences. However, because the ICC can be difficult to interpret because of binary outcomes, the partition of variance between different levels does not have the intuitive interpretation of the linear model. We therefore also calculated the MOR, defined as the median value of the odds ratio between the hospital at highest risk (longest time interval) and the hospital at lowest risk when randomly picking out two hospitals. The MOR can be conceptualised as the increased risk (in median) that a patient would have if moved to a hospital with a higher risk \[[@CR24]\]. The measure of fixed effect was the odds ratio (OR) with 95 % confidence intervals. A *p*-value lower than 0.05 was considered statistically significant for all statistical analyses. Data analyses were performed using SPSS statistical software, version 20.0 (SPSS INC., Chicago, IL, USA) and Stata v12 (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP).

Results {#Sec3}
=======

Of the 502 patients recruited, 32 were excluded because they did not meet the inclusion criteria. The study group was therefore composed of 470 patients. Mean age was 67.8 years (SD:7.6), 337 (71.9 %) had completed at least primary studies, and 347 (73.8 %) were retired (Table [2](#Tab2){ref-type="table"}). The mean BMI was 28.1 (SD:4.5) and 354 (75.4 %) had no physical limitations according to the ECOG WHO performance status. The Charlson comorbidity index was between one and three for 451 participants (96.2 %). Prostate screening was performed in primary care settings for 355 of the 470 patients (75.5 %), and in hospital settings for 86 of these participants (18.3 %). In 53.4 % of patients, the disease was identified during a routine visit or during consultation for another cause because no symptoms or only discomfort caused by prostate cancer had been noted. The median PSA value for the patients without symptoms was 7.2 (IQR: 6.9). From the total group, 36.2 % were symptomatic; 48.1 % of these patients had lower urinary tract symptoms such as increased frequency of urination (16.3 %), and 7.6 % had symptoms related to the tumour. The time from the first symptom to first consultation was between one month and one year for 50.8 % of participants. The clinical stage of the primary tumour was T1a-c in 41.0 % cases and T2 a-c in 40 % cases; 2.3 % had regional lymph nodes (N1) and 2.3 % had distant metastases (M1). The median PSA value was 7.6 (IQR: 7.8) ng/mL and the total Gleason score was between two and six for 55.6 % of participants. According to the D'Amico classification, 36.1 % of patients had low-risk cancer and 39.4 % had high-risk cancer (Table [2](#Tab2){ref-type="table"}).Table 2Characteristics of prostate cancer patientsVariables*N* = 470n (%)Mean age ± SD67.8 ± 7.6Missing (%):2.3Mean BMI ± SD28.1 ± 4.5Missing (%)3.8Working statusActive83 (17.7)Sick leave15 (3.1)Retired347 (73.8)Unemployed17 (3.6)Other4 (0.9)Missing4 (0.9)Education (%)No education47 (10.2)Incomplete primary education80 (17.2)Primary education109 (23.5)Graduate school99 (21.3)Upper secondary studies62 (13.4)University67 (14.5)Missing6 (1.2)Setting first consultation (%)Primary care355 (75.5)Hospital86 (18.5)Other23 (5.0)Missing6 (1.2)Symptoms (%)No symptoms or discomfort251 (53.4)One or more symptoms170 (36.2)Missing49 (10.4)Start of first symptoms including patients with discomfort (%)Since one month55 (11.7)Between one month and one year242 (51.4)Later than a year56 (12.0)No symptoms68 (14.5)Missing49 (10.4)ECOG WHO (%)Fully active:356 (75.7)Restricted or worse:105 (22.3)Missing:9 (2.0)Charlson index (%)1:358 (75.8)2:68 (14.4)3:26 (5.5)4:13 (2.8)≥5:5 (1.5)Median PSA (ng/mL) ± IQR7.6 ± 7.8Missing (%):3.4Total Gleason (%)2-6:262 (55.6)7:127 (26.9)\>7:74 (15.6)Missing:7 (1.9)Median total Gleason ± IQR6.0 ± 1.0Primary tumour clinical stage (T) (%)Tx:1 (0.2)T1a-c194 (41.0)T2a-c:189 (40.1)T3a-b :74 (15.7)T4:8 (1.7)Missing:4 (1.3)Regional lymph nodes clinical stage (N) (%)Nx-N0:460 (97.7)N1:10 (2.3)Missing:0 (0.0)Distance metastasis clinical stage (M) (%)Mx-M0:460 (97.9)M1a-c:10 (2.1)Missing:0 (0.0)D'Amico Classification (%)Low risk:170 (36.1)Medium risk:115 (24.5)High risk:185 (39.4)Missing:0 (0.0)Median time between first consultation and diagnosis in days ± IQR89.0 ± 123.5Missing (%):4.0Median time between diagnosis and first treatment in days ± IQR75.0 ± 78.0Missing (%):3.2Median time between first consultation and first treatment in days ± IQR176.0 ± 151.0Missing (%):6.6

All patients had a prostate biopsy and 82.9 % underwent a prostate ultrasound study. A renal ultrasonography was performed in 23.8 % of patients and a bladder ultrasonography in 22.5 % (Table [3](#Tab3){ref-type="table"}). Table [4](#Tab4){ref-type="table"} shows the patients' characteristics for each participating hospital. The median diagnostic interval was 89.0 days (IQR: 123.5). No statistically significant differences were found between hospitals for this interval (MOR: 1.00). Patients with one or more symptoms had an OR of 1.93 (95 % CI 1.29--2.89, *P* = 0.001) of having an interval between first consultation and diagnosis of more than 100 days (Table [5](#Tab5){ref-type="table"}). No significant differences were found for groups of patients differing in age, BMI, education level, ECOG WHO score, the specialist at first consultation, primary tumour stage, PSA, or total Gleason scores.Table 3Diagnostic variables of prostate cancer patientsDiagnostic test*N* = 470n (%)Ultrasound (%)Prostate ultrasound:390 (82.9)Renal ultrasound:112 (23.8)Bladder ultrasound:106 (22.5)Puncture (%)Biopsy:464 (98.7)Aspiration:32 (6.8)Scintigraphy (%)63 (13.4)Nuclear magnetic resonance (%)Abdominal:66 (14.0)Thoracic:1 (0.2)Cranial:1 (0.2)CT scan (%)Abdominal:30 (6.4)Abdominothoracic:33 (7.0)Toracic:14 (3.0)Cranial:3 (0.6)Table 4Characteristics of prostate cancer patients by hospitalsCentresA (*n* = 48)B (*n* = 91)C (*n* = 37)D (*n* = 78)E (*n* = 112)F (*n* = 33)G (*n* = 75)Mean age ± SD72.6 ± 6.166.9 ± 7.767.3 ± 5.667.8 ± 6.767.1 ± 7.866.2 ± 6.967.6 ± 9.2Missing (%):0.02.20.05.10.06.14.1Mean BMI ± SD28.2 ± 5.727.3 ± 3.527.6 ± 3.828.8 ± 6.428.9 ± 4.127.6 ± 4.327.2 ± 2.9Missing (%):0.04.40.03.80.921.24.1Median PSA (ng/mL) ± IQR10.4 ± 15.55.7 ± 3.46.7 ± 3.77.8 ± 7.78.6 ± 12.27.0 ± 3.88.7 ± 8.2Missing (%):2.18.80.06.40.03.01.4ECOG WHO (%)Fully active:72.984.691.971.869.663.675.3Restricted or worse:25.015.48.123.130.433.317.8Missing:2.10.00.05.10.03.06.8Primary tumour clinical stage (T) (%)Tx:0.00.00.01.31.30.00.0T1a-c45.845.116.237.237.243.841.1T2a-c:43.839.656.837.237.233.019.3T3a-b :6.314.321.620.520.522.36.8T4:4.11.00.03.83.80.91.4Missing:0.00.05.40.00.00.01.4Regional lymph nodes clinical stage (N) (%)Nx-N0:100.098.9100.092.3100.0100.097.3N1:0.01.10.07.70.00.02.7Missing:0.00.00.00.00.00.00.0Distance metastasis clinical stage (M) (%)Mx-M0:95.8100.0100.093.698.2100.098.6M1a-c:4.20.00.06.41.80.01.4Missing:0.00.00.00.00.00.00.0D'Amico Classification (%)Low risk:14.650.554.132.139.336.421.9Medium risk:27.112.129.717.923.245.534.2High risk:58.337.416.250.037.518.142.5Missing:0.00.00.00.00.00.01.4Total Gleason (%)2-6:16.773.664.968.066.936.431.57:29.219.829.717.918.851.543.8\>7:54.16.62.710.214.39.119.2Missing:0.00.02.73.90.03.05.5Median total Gleason ± IQR8.0 ± 1.06.0 ± 1.06.0 ± 1.06.0 ± 2.06.0 ± 1.07.0 ± 1.07.0 ± 1.0Median time between first consultation and diagnosis in days ± IQR99.5 ± 139.079.0 ± 211.0110.0 ± 117.078.5 ± 107.392.0 ± 99.0133.0 ± 195.076.5 ± 100.0Missing (%):0.03.35.47.74.56.11.4Median time between diagnosis and first treatment in days ± IQR30.5 ± 127.578.0 ± 62.083.0 ± 72.0104.0 ± 70.555.0 ± 66.573.5 ± 84.570.0 ± 95.0Missing (%):0.04.40.01.36.33.02.7Median time between first consultation and first treatment in days ± IQR164.0 ± 232.0154.0 ± 207.0212.0 ± 165.0200.0 ± 130.0166.0 ± 112.8203.0 ± 149.8165.0 ± 128.5Missing (%):0.06.65.49.08.99.14.1Table 5Time interval between first consultancy and diagnosis and potential determinant (Univariate regression)ICC/MOR95 % CI MOR*P*-valueHospital random effect0.00Empty model1.001.00--1.001.000Median (days)IQR (days)OR \>100 days95 % CI ORAge\<65 years84.0182.01≥65 years91.0105.50.960.64--1.430.830BMI\<25102.0163.01≥2586.0110.30.640.40--1.010.057Education levelPrimary education or lower90.5108.51Graduate school or higher86.0139.01.000.69--1.450.992ECOG WHO ScoreFully active87.5126.81Restrictive or worse95.0129.01.180.76--1.830.474Specialist first consultationPrimary care91.0139.51Hospital or specialist79.0106.00.780.50--1.220.277Primary tumour clinical stage (T)T1a--T1c95.5141.31T2a--T485.0108.50.730.50--1.070.110PSA value\<1095.0135.51≥1084.0108.50.810.54--1.210.310Total Gleason score\<787.0140.01≥791.0111.50.870.60--1.270.464SymptomsNo symptoms or discomfort83.0110.01One or more symptoms110.0174.01.931.29--2.890.001

The median therapeutic interval was 75 days (IQR: 78.0) (Table [5](#Tab5){ref-type="table"}). No statistically significant association was found between groups for this interval regarding age, BMI, education level, specialist at first consultation, or primary tumour stage (Table [6](#Tab6){ref-type="table"}). A higher PSA value and a higher Gleason score shortened the interval between diagnosis and treatment. Patients with a PSA value higher than 10 or a total Gleason score higher than 7 had an OR of 0.5 (95 % CI 0.29--0.86, *P* = 0.012) and 0.53 (95 % CI 0.30--0.93, *P* = 0.026), respectively, to have an interval between diagnosis and treatment of more than 30 days. The MOR for the random effect of the hospital where the patient received care was 2.16 (95 % CI 1.45--4.87, *P* = 0.000).Table 6Time interval between diagnosis and first treatment and potential determinantsCharacteristicUnivariate regressionMultivariate regressionHospital random effectEmpty model ICC/MOR95 % CI MOR*P*-valueFInal model ICC/MOR95 % CI MOR*P*-value0.18/2.221.52--4.580.0000.17/2.161.45--4.870.000Median (days)IQR (days)OR \>30 days95 % CI OROR \>30 days95 % CI ORAge\<65 years78.074.01≥65 years71.079.00.700.40--1.210.198BMI\<2575.076.01≥2572.081.01.060.60--1.900.831Education levelPrimary education or lower76.077.81Graduate school or higher70.077.51.250.76--2.060.386ECOG WHO ScoreFully active77.074.81Restrictive or worse54.077.00.550.32--0.950.033Specialist first consultationPrimary care76.077.01Hospital or specialist74.079.50.860.48--1.560.621Primary tumour clinical stage (T)T1a--T1c84.077.01T2a--T469.079.00.590.35--0.980.040PSA value\<1086.075.01≥1050.081.00.410.24--0.680.0010.500.29--0.860.012Gleason score\<785.568.81≥755.088.00.420.25--0.710.0010.530.30--0.930.026SymptomsNo symptoms or discomfort78.072.01One or more symptoms73.580.30.620.37--1.050.073

Discussion {#Sec4}
==========

This multicentre cohort study aimed to describe the healthcare process in patients with prostate cancer in Spain. We focused on the characteristics of patients and tumours and we evaluated diagnosis and treatment delays in healthcare.

Our study included 470 patients diagnosed with prostate adenocarcinoma in a hospital care setting. Prostate biopsy and ultrasound were the most frequently performed diagnostic tests. The mean age of our population, the proportion of asymptomatic low risk patients and the median Gleason grade were similar to those reported in previous studies in Spain and in other countries \[[@CR16], [@CR19], [@CR25]--[@CR29]\]. The percentage of localised tumours in our population (81 %) was similar to that in an earlier study (89.8 %) in Spain conducted by Cozar *et al.* but considerably higher than that in the European study of Gatta *et al.* These discordant findings might be explained by differences between countries and years regarding accessibility to health services and physicians' attitudes towards screening tests \[[@CR30]\].

In our study, clinical symptoms were present in 36.2 % of all patients, the most common symptom being disorders of the lower urinary tract (48.1 %) and symptoms related with the tumour (7.6 %). These results are similar to those in the study of Cozar *et al.* where the frequency of lower urinary tract symptoms was 39.5 % of patients and the frequency of symptoms related to the tumour was 11.6 % \[[@CR16]\]. In our study, the median interval between first consultation and diagnosis was 89.0 days, comparable to the 72 days in the study by Hansen et al. \[[@CR31]\] and the 101 days reported by Torring et al. \[[@CR32]\].

We did not find any variability in diagnostic interval between hospitals regarding age, BMI, education level, first visit with a specialist, tumour stage, PSA value, or Gleason score. However, the presence of symptoms lengthened this interval possibly because some symptoms of prostate cancer can be confused with benign prostatic hyperplasia.

Previous studies in Spain that determined the therapeutic intervals in cancer patients were generally conducted in a single hospital \[[@CR33]--[@CR35]\]. The most recently published multicentre study analysed this interval for six types of cancer, including prostate cancer \[[@CR19]\], and found the mean therapeutic interval was longer than in our study (102.5 days (SD:71.6) vs. 80.4 days (SD:60.9)). However, we defined this interval as the time between the biopsy and the first oncological treatment, whereas the investigators in the previous study defined it as the time between the first diagnostic test of any kind and first oncological treatment. In contrast with the study by Perez *et al*. \[[@CR19]\], our study was prospective, it had a larger number of cases, patients were from several different autonomous regions of the country, and information was obtained not only from medical records but also through patient interviews.

We observed that patients with a higher PSA value and a higher Gleason score had a shorter interval between diagnosis and first treatment than patients with lower values. Pérez et al. \[[@CR19]\] reported similar findings in patients with advanced stages of prostate cancer. An explanation for this shorter interval could be that due to their worse prognosis, these patients usually receive hormonal therapy initially or exclusively, a treatment that is easier to administer **t**han radiotherapy, chemotherapy, or surgery \[[@CR36]\].

Our results show a statistically significant variability between centres in relation to the therapeutic interval. The heterogeneity in intervals could be associated with the wide diversity in population characteristics, healthcare organisation and clinical policies in the different regions in Spain.

One of the main strengths of our study is that our sample of patients is a representative sample of the approximately 28.000 yearly incident prostatic cancer patients diagnosed in Spain because they were recruited from seven hospitals in five autonomous regions. In addition, the study's prospective nature guarantees consistency and accuracy of the data collected, surpassing the common shortcomings of a retrospective collection of information. The study may have limitations, however, such as information bias. Given that it is based exclusively on information obtained in a hospital setting, outpatient factors such as those related to consultation at a primary level, could not have been taken into consideration. Nevertheless, as urologic cancer care is mainly provided in the hospital setting, in our view this limitation has little practical relevance.

Conclusions {#Sec5}
===========

Most incident prostate cancer patients in Spain are diagnosed at an early stage of an adenocarcinoma. The period to complete the diagnostic process is approximately three months whereas the therapeutic intervals vary among centres and are shorter for patients with a worse prognosis. The presence of prostatic symptoms, PSA level, and Gleason score influence the clinical intervals differently.
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